PT-141 10mg

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist derived from α-melanocyte-stimulating hormone (α-MSH). It has been studied in preclinical and clinical research for its activity at central melanocortin receptors, particularly MC3R and MC4R, which are involved in neuroendocrine signaling pathways.

Research has examined PT-141 for its role in central nervous system–mediated mechanisms related to sexual behavior and arousal. Unlike phosphodiesterase type-5 (PDE5) inhibitors, PT-141 has been investigated for its receptor-based mechanism that does not rely on peripheral vascular pathways, making it a compound of interest in comparative pathway studies.

Pharmacokinetic and pharmacodynamic evaluations in controlled research environments have explored its onset characteristics and receptor activation profile. Safety and tolerability outcomes have been reported in both preclinical and clinical studies, with observations documented under regulated study conditions.

This peptide is supplied as a lyophilized powder to support stability for laboratory and research use.